The Asia Pacific aortic valve replacement devices market is expected to grow from US$ 1,323.15 million in 2022 to US$ 3,489.38 million by 2030. It is estimated to grow at a CAGR of 12.9% from 2022 to 2030.
Asi
Based on product, the Asia Pacific aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger Asia Pacific aortic valve replacement devices market share in 2022.
Based on surgery, the Asia Pacific aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger Asia Pacific aortic valve replacement devices market share in 2022.
Based on end user, the Asia Pacific aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest Asia Pacific aortic valve replacement devices market share in 2022.
Based on country, the Asia Pacific aortic valve replacement devices market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific aortic valve replacement devices market in 2022.
Abbott Laboratories, Artivion Inc, Boston Scientific Corp, Edwards Lifesciences Corp, LivaNova Plc, Medtronic Plc, and Venus MedTech HangZhou Inc, are some of the leading companies operating in the Asia Pacific aortic valve replacement devices market.
Reasons to Buy
Advancements in Aortic Valve Replacement Devices Fuels Asia Pacific Aortic Valve Replacement Devices Market
The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.A few technological advancements by the players in the aortic valve replacement devices are mentioned below:
- In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.
- In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
- In August 2021, the first Made in India 3D printed heart valve was developed in Chennai. The new heart valves were developed using 3D printers, which could overcome the problems related to artificial heart valves. Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.
Asia Pacific Aortic Valve Replacement Devices Market Overview
The Asia Pacific aortic valve replacement devices market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The region holds a significant share of the global aortic valve replacement devices market. The market in Asia Pacific is expected to witness significant growth during the forecast period due to factors such as rising elderly population, growing cardiovascular diseases, and innovative product availability.Asi
a Pacific Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Aortic Valve Replacement Devices Market Segmentation
The Asia Pacific aortic valve replacement devices market is segmented into product, surgery, end user, and country.Based on product, the Asia Pacific aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger Asia Pacific aortic valve replacement devices market share in 2022.
Based on surgery, the Asia Pacific aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger Asia Pacific aortic valve replacement devices market share in 2022.
Based on end user, the Asia Pacific aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest Asia Pacific aortic valve replacement devices market share in 2022.
Based on country, the Asia Pacific aortic valve replacement devices market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific aortic valve replacement devices market in 2022.
Abbott Laboratories, Artivion Inc, Boston Scientific Corp, Edwards Lifesciences Corp, LivaNova Plc, Medtronic Plc, and Venus MedTech HangZhou Inc, are some of the leading companies operating in the Asia Pacific aortic valve replacement devices market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific aortic valve replacement devices market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific aortic valve replacement devices market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the aortic valve replacement devices market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Aortic Valve Replacement Devices Market Landscape
5. Asia Pacific Aortic Valve Replacement Devices Market - Key Industry Dynamics
6. Aortic Valve Replacement Devices Market - Asia Pacific Market Analysis
7. Asia Pacific Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 - by Product
8. Asia Pacific Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 - by Surgery.
9. Asia Pacific Aortic Valve Replacement Devices Market - Revenue and Forecast to 2030 - by End User.
10. Asia Pacific Aortic Valve Replacement Devices Market - Country Analysis
11. Asia Pacific Aortic Valve Replacement Devices Market Industry Landscape
12. Key Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Artivion Inc
- Boston Scientific Corp
- Edwards Lifesciences Corp
- LivaNova Plc
- Medtronic Plc
- Venus MedTech HangZhou Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 87 |
| Published | January 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1323.15 Million |
| Forecasted Market Value ( USD | $ 3489.38 Million |
| Compound Annual Growth Rate | 12.9% |
